Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03694119 · ClinicalTrials.gov registry record · Phase 1
Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
NCT03694119 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 92 participants.
The verdict
NCT03694119, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the potential effect of ozanimod on pressor response when co-administered with oral tyramine in healthy adult subjects. Study Design This is a Phase 1, randomized, double-blind (subjects and study site personnel \[except pharmacist or designee\] are blinded to the treatments until 7 ± 2 days postdose follow-up), placebo- and positive-controlled study. Study design is described below: Subjects will be screened for participation in this study within 28 days prior to dosing in Period 1. Period 1: To exclude subjects with very low or very high sensitivity to tyramine, oral tyramine pressor tests will be performed prior to randomization on all subjects after eligibility has been confirmed at Screening (in the absence of any other investigational product \[IP\] treatment) to determine the pressor response to tyramine. The pressor response, referred to hereafter as Tyr30, is defined as the tyramine dose required to increase systolic blood pressure (SBP) by at least 30 mm Hg from daily defined baseline in three consecutive measurements within 4 hours after tyramine dosing. The test consists of daily administration of escalating doses of tyramine (up to 10 days) until a sustained SBP increase of ≥ 30 mm Hg is observed relative to the daily-defined baseline values. Sustained increase is determined by 3 consecutive SBP measurements within 4 hours after tyramine administration. The daily-defined baseline SBP value is defined as the average of five SBP measurements with approximately 5-minute interval after an initial 10- minute rest in the supine position and within 30 minutes prior to tyramine administration. Only subjects who present Tyr30 ≥ 200 mg and ≤ 800 mg will then be randomized. Subjects will be randomized into one of three treatment groups (phenelzine, ozanimod, or placebo) in a 1:1:1 fashion while stratifying for sex in such a manner that each treatment will have a minimum of 30% of either sex. Period 2: Subjects will re
Interventions
- DRUG Phenelzine
- DRUG ozanimod
- DRUG ozanimod placebo
- DRUG Tyramine
- DRUG Phenelzine placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2018-07-24 |
| Est. Completion | 2019-01-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03694119
The ClinicalTrials.gov registry entry for NCT03694119 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Phenelzine is the first listed.
NCT03694119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03694119 about?
NCT03694119 is a clinical study titled "Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response". The purpose of this study is to evaluate the potential effect of ozanimod on pressor response when co-administered with oral tyramine in healthy adult subjects. Study Design This is a Phase 1, randomized, double-blind (subjects and study site personnel \[except pharmacist or designee\] are blinded ...
What is the current status of trial NCT03694119?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2018-07-24. Estimated completion is 2019-01-08.
What interventions are being tested in trial NCT03694119?
The interventions under investigation include: Phenelzine (DRUG), ozanimod (DRUG), ozanimod placebo (DRUG), Tyramine (DRUG), Phenelzine placebo (DRUG).
Who is sponsoring clinical trial NCT03694119?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.